Learn More About Our Breast Cancer Trials

• 1 S1207 Show More

  S1207 – Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer.

  1. WHAT TYPE OF CANCER? WHAT STAGE?
  Early Stage Breast Cancer (Stage I, II, and III)

  2. WHO IS ELIGIBLE?
  Women who are ER/PR+ but Her2-

  3. HOW WILL I BE TREATED?
  Women may also receive Everolimus (an mTOR inhibitor)

  For Physicians: More information about this specific trial at clinicaltrials.gov

• 2 A5481082 Show More

  A5481082 Palbociclib in Hormone Receptor Postive Advanced Breast Cancer: A Prospective Multi center Non-Interventional Study

  1. WHAT TYPE OF CANCER? WHAT STAGE?
  Triple Negative Breast Cancer

  2. WHO IS ELIGIBLE?
  Women with Inoperable or Metastatic disease

  3. HOW WILL I BE TREATED?
  Women may also receive palcociclib (Ibrance), which is used to treat ER+ breast cancer

  For Physicians: More information about this specific trial at clinicaltrials.gov